Preventive injection of some types of pain-relief drugs around knee joint for management of pain after complete replacement of knee joint.

Preemptive Injection of Periarticular-Multimodal Drug for Postoperative Pain Management in Total Knee Arthroplasty: A double-blind randomized clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016073129132N2

Enrollment

120

Registered

2016-08-24

Start date

2014-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Arthrosis of knee (Gonarthrosis). Condition 2: Severity of pain after Total Knee Arthroplasty. Condition 3: Total Knee Arthroplasty. Other primary gonarthrosis Other complications of internal orthopaedic prosthetic devices, implants and grafts Presence of other specified functional implants

Interventions

Intervention 1: Intervention group: Intervention Name: Preemptive Injection of Periarticular-Multimodal Drug Intervention Description:Injection of a cocktail including Bupivacaine hydrochloride 0.5%

Treatment - Drugs

Intervention group: Intervention Name: Preemptive Injection of Periarticular-Multimodal Drug Intervention Description:Injection of a cocktail including Bupivacaine hydrochloride 0.5% (AstraZeneca,

Control group: Intervention name: Routinely preemptive Injection Intervention discription: Preemptive Injection of Epinephrine (1:1000) that also been diluted in 0.9 % sodium chloride to make a tota

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: individuals with osteoarthritis who were scheduled for primary unilateral TKA. Exclusion criteria: BMI greater than 40; previous history of allergy to any medications; known abuser of alcohol and other drugs; any inflammatory arthritis; previous major surgery in the same knee joint indicated for TKA; individuals who were candidated for bilateral TKA; patients who did not show up for the follow-up.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The severity of the pain in knee joint. Timepoint: 24 hours, 48 hours and 6 weeks after the surgery. Method of measurement: Visual Analog Scale (VAS).	—

Secondary

Measure	Time frame
Function of knee joint. Timepoint: 6 weeks and 6 months after surgery. Method of measurement: Knee Society Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSajad Badiei

Isfahan University of Medical Sciences

s_badiei@edc.mui.ac.ir+98 31 3264 4568

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026